Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617595 | NODEN PHARMA | Galenic formulations of organic compounds |
Feb, 2026
(2 years from now) | |
US8617595 (Pediatric) | NODEN PHARMA | Galenic formulations of organic compounds |
Aug, 2026
(2 years from now) |
Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient
Market Authorisation Date: 05 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9023893 | NODEN PHARMA | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Mar, 2022
(1 year, 6 months ago) | |
US8618172 | NODEN PHARMA | Galenical formulations of organic compounds |
Jul, 2028
(4 years from now) |
Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 18 January, 2008
Treatment: NA
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic